BIOCELTIX S.A. ZY -10 Cash Flow Conversion Efficiency

Latest as of December 2025: -0.062x

BIOCELTIX S.A. ZY -10 cash flow conversion efficiency. Based on the latest financial reports, BIOCELTIX S.A. ZY -10 (XI3) has a cash flow conversion efficiency ratio of -0.062x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.54 Million ≈ $-5.31 Million USD) by net assets (€73.28 Million ≈ $85.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of BIOCELTIX S.A. ZY -10 (2021–2025)

Cash flow conversion efficiency of BIOCELTIX S.A. ZY -10 from 2021 to 2025. This chart illustrates how BIOCELTIX S.A. ZY -10's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XI3 live share price for real-time trading data and today's change.

BIOCELTIX S.A. ZY -10 Cash Flow Conversion Ratio Explained

BIOCELTIX S.A. ZY -10 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

BIOCELTIX S.A. ZY -10 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BIOCELTIX S.A. ZY -10 ranked by their cash flow conversion efficiency. Also see BIOCELTIX S.A. ZY -10 stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Mahachai Hospital Public Company Limited BK:M-CHAI	0.165x
Hexa Tradex Limited NSE:HEXATRADEX	0.000x
Right Way Industrial Co Ltd TW:1506	0.008x
Fima Corporation Bhd KLSE:3107	0.110x
Hsinli Chemical Industrial TWO:4303	0.015x
Three A Resources Bhd KLSE:0012	0.049x
Genelux Corporation Common Stock NASDAQ:GNLX	-0.264x
CURATIS N AG SW:CURN	-0.024x

Annual Cash Flow Conversion Efficiency for BIOCELTIX S.A. ZY -10 (2021–2025)

The table below shows the annual cash flow conversion efficiency of BIOCELTIX S.A. ZY -10 from 2021 to 2025. Review XI3 FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€73.28 Million ≈ $85.67 Million	€-11.95 Million ≈ $-13.97 Million	-0.163x	+64.34%
2024-12-31	€38.42 Million ≈ $44.91 Million	€-17.57 Million ≈ $-20.54 Million	-0.457x	+67.55%
2023-12-31	€10.47 Million ≈ $12.24 Million	€-14.75 Million ≈ $-17.24 Million	-1.409x	+7.84%
2022-12-31	€5.15 Million ≈ $6.02 Million	€-7.87 Million ≈ $-9.21 Million	-1.529x	-128.26%
2021-12-31	€6.00 Million ≈ $7.01 Million	€-4.02 Million ≈ $-4.70 Million	-0.670x	--

About BIOCELTIX S.A. ZY -10

F:XI3 Germany Biotechnology

Market Cap

$131.94 Million

€112.86 Million EUR

Market Cap Rank

#19434 Global

#1788 in Germany

Share Price

€20.40

Change (1 day)

+6.36%

52-Week Range

€14.08 - €24.35

All Time High

€28.60